ENT Liu Knowledge Base Head & neck tumours · physician reviewed
HPV-Associated Oropharyngeal Cancer · Understanding the disease

What is HPV-associated oropharyngeal cancer?

Reviewed: 8 November 2026 By: Xiangpeng Liu, MD Topic: HPV-Associated Oropharyngeal Cancer Answer length: short, citable
Quick answer

HPV-associated oropharyngeal cancer is a squamous cell carcinoma of the tonsils or base of tongue caused by persistent high-risk human papillomavirus, usually HPV-16. It is the fastest-growing head and neck cancer in North America and Northern Europe, often affects non-smoking men aged 40–60, and has a markedly better prognosis than HPV-negative tumours.

In detail

The oropharynx includes the palatine tonsils, base of tongue, soft palate and the side and back walls of the throat. In high-income countries, most cancers here are now driven by HPV-16 rather than by tobacco and alcohol. Because the tonsil crypts can hide a very small primary tumour, the first sign is frequently a painless, cystic lump in the neck rather than a visible throat sore.

HPV-positive disease is a distinct biological entity. It has a separate AJCC 8th-edition staging system, responds better to radiotherapy and chemoradiotherapy, and carries roughly 85% five-year overall survival in published cohorts. All oropharyngeal squamous cell carcinomas should be tested for p16 by immunohistochemistry; confirmatory HPV DNA or RNA testing is recommended when the result changes management or trial eligibility.

What this means in practice: this answer is part of the “Understanding the disease” section of the HPV-Associated Oropharyngeal Cancer topic. If you are comparing treatment options, also read how to compare a second opinion and which records to send.

Other common questions about HPV-associated oropharyngeal cancer

See all 16 questions in this topic →

Sources for this answer

  1. Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 CA: A Cancer Journal for Clinicians · 2026 · Subsite-level estimates for 185 countries; the basis of the regional atlas on this site.
  2. HPV & Oropharyngeal Cancer US National Institute of Dental and Craniofacial Research · 2025 · About 70% of oropharyngeal cancers in the United States are HPV-positive.
  3. HPV Detection in Oropharyngeal Cancer: A Narrative Review PubMed Central / peer-reviewed review · 2025 · HPV-attributable fraction: ~71% US, ~52% UK, >60% Scandinavia, <20% Southern Europe, ~44% globally.
  4. Impact of screening for HPV-positive oropharyngeal cancers: a microsimulation-based modeling study Journal of the National Cancer Institute · 2025 · Reports ~85% 5-year overall survival for HPV-positive oropharyngeal cancer.

Written and medically reviewed by Xiangpeng Liu, MD

Associate Chief Physician, ENT & Head/Neck Surgery · Chenzhou First People’s Hospital, Chenzhou, Hunan, China

Editorial policy & reviewer credentials · All sources

← Topic overviewBack to HPV-Associated Oropharyngeal Cancer Next question →Where in the world is HPV-associated oropharyngeal cancer most common?

Need an opinion on your own case?

International patients can request a preliminary review based on pathology and imaging before travelling to China.

How the pathway works Send an enquiry

Medical disclaimer: This knowledge base is general information for people researching head and neck tumours, not a diagnosis or treatment plan. It does not replace an examination by a qualified physician. Survival figures are population averages, not predictions for an individual. Treatment and cost estimates for China are illustrative only and must be confirmed in writing after your records have been reviewed. If you have a symptom lasting more than two to three weeks, see a doctor promptly.